West Pharmaceutical Services (WST) Margin Decline Tests Bullish High P E Narrative

West Pharmaceutical Services (WST) experienced a decline in its net profit margin to 16.1% in Q4 2025, down from 17% a year prior, despite quarterly revenue growth. The company trades at a high P/E ratio of 45.2x, significantly above industry and peer averages, and its share price of US$309.70 exceeds its DCF fair value estimate of US$190.73. Analysts forecast a 6.6% annual revenue growth, which lags the broader U.S. market’s 10.9%, raising concerns about its valuation given the softening margins and slower projected growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin